Payment overview · 2025
General Payments
$301.32
17 reported records · 6 companies
Healthcare provider profile · identity verified
Devonna Giles Maguet, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · CORBIN, KY · NPI 1992066559
Verified facts
What the public records show
CMS Open Payments records show Devonna Giles Maguet, APRN received $301.32 in general payments during 2025 across 17 reported records.
AstraZeneca Pharmaceuticals LP accounted for 59.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Trelegy Ellipta, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ubrelvy by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $179.61 | 59.6% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $50.72 | 16.8% | 3 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $23.58 | 7.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.76 | 5.6% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $16.16 | 5.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.49 | 4.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $301.32 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $59.53 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $32.44 | 2 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $23.58 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $18.28 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.28 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $16.76 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $16.16 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 49 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 60 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
71 | 16 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
60 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
97 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 874 | 96 |
| Gabapentin | Gabapentin | 757 | 80 |
| Pantoprazole Sodium | Pantoprazole Sodium | 342 | 80 |
| Amlodipine Besylate | Amlodipine Besylate | 288 | 69 |
| Levothyroxine Sodium | Levothyroxine Sodium | 278 | 67 |
| Atorvastatin Calcium | Atorvastatin Calcium | 262 | 66 |
| Losartan Potassium | Losartan Potassium | 245 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 242 | 55 |
| Lisinopril | Lisinopril | 230 | 53 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 214 | 54 |
| Potassium Chloride | Potassium Chloride | 212 | 44 |
| Tizanidine Hcl | Tizanidine Hcl | 200 | 44 |
| Omeprazole | Omeprazole | 198 | 44 |
| Ropinirole Hcl | Ropinirole Hcl | 198 | 25 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 177 | 82 |
| Metformin Hcl | Metformin Hcl | 168 | 44 |
| Quetiapine Fumarate | Quetiapine Fumarate | 166 | 30 |
| Bumetanide | Bumetanide | 165 | 44 |
| Glipizide Er | Glipizide | 155 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 148 | 27 |
| Famotidine | Famotidine | 148 | 37 |
| Pregabalin | Pregabalin | 144 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 141 | 37 |
| Celecoxib | Celecoxib | 140 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 139 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 138 | 36 |
| Promethazine Hcl | Promethazine Hcl | 138 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 136 | 44 |
| Eliquis | Apixaban | 135 | 24 |
| Ibuprofen | Ibuprofen | 134 | 30 |
| Sertraline Hcl | Sertraline Hcl | 130 | 31 |
| Progesterone | Progesterone, Micronized | 126 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 122 | 26 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 122 | 29 |
| Ventolin Hfa | Albuterol Sulfate | 122 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 121 | 29 |
| Meloxicam | Meloxicam | 121 | 30 |
| Ozempic | Semaglutide | 120 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 112 | 24 |
| Furosemide | Furosemide | 107 | 29 |
| Azithromycin | Azithromycin | 106 | 69 |
| Estradiol | Estradiol | 105 | 22 |
| Methylprednisolone | Methylprednisolone | 104 | 68 |
| Montelukast Sodium | Montelukast Sodium | 102 | 27 |
| Mounjaro | Tirzepatide | 97 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 97 | 26 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 97 | 34 |
| Spironolactone | Spironolactone | 93 | 20 |
| Lorazepam | Lorazepam | 91 | 13 |
| Carvedilol | Carvedilol | 89 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 88 | 23 |
| Diclofenac Sodium | Diclofenac Sodium | 87 | 38 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 87 | 21 |
| Ondansetron Hcl | Ondansetron Hcl | 87 | 24 |
| Bupropion Hcl Sr | Bupropion Hcl | 86 | 19 |
| Donepezil Hcl | Donepezil Hcl | 84 | 17 |
| Simvastatin | Simvastatin | 84 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 84 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 82 | 49 |
| Escitalopram Oxalate | Escitalopram Oxalate | 80 | 22 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 80 | 17 |
| Alprazolam | Alprazolam | 78 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 77 | 22 |
| Ondansetron Odt | Ondansetron | 76 | 28 |
| Tramadol Hcl | Tramadol Hcl | 74 | 18 |
| Prednisone | Prednisone | 73 | 20 |
| Linzess | Linaclotide | 71 | 16 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 70 | 13 |
| Buspirone Hcl | Buspirone Hcl | 69 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 68 | 15 |
| Allopurinol | Allopurinol | 65 | 11 |
| Cephalexin | Cephalexin | 65 | 40 |
| Trazodone Hcl | Trazodone Hcl | 65 | 16 |
| Nystatin | Nystatin | 64 | 27 |
| Meclizine Hcl | Meclizine Hcl | 63 | 26 |
| Methocarbamol | Methocarbamol | 62 | suppressed |
| Jardiance | Empagliflozin | 60 | 12 |
| Cefdinir | Cefdinir | 55 | 33 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 55 | 39 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 54 | suppressed |
| Baclofen | Baclofen | 53 | 17 |
| Ezetimibe | Ezetimibe | 52 | suppressed |
| Gemfibrozil | Gemfibrozil | 52 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 51 | 13 |
| Farxiga | Dapagliflozin Propanediol | 49 | suppressed |
| Mupirocin | Mupirocin | 48 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 45 | 26 |
| Topiramate | Topiramate | 45 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 45 | 12 |
| Etodolac | Etodolac | 44 | suppressed |
| Fluconazole | Fluconazole | 44 | 22 |
| Glipizide | Glipizide | 44 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 42 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 42 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 40 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 40 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 40 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 39 | suppressed |
| Bupropion Xl | Bupropion Hcl | 38 | suppressed |
| Januvia | Sitagliptin Phosphate | 38 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 37 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 37 | suppressed |
| Levofloxacin | Levofloxacin | 36 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Finasteride | Finasteride | 35 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 32 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 32 | suppressed |
| Clonazepam | Clonazepam | 31 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Amoxicillin | Amoxicillin | 29 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 29 | suppressed |
| Levetiracetam | Levetiracetam | 29 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 29 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 29 | 15 |
| Colchicine | Colchicine | 28 | suppressed |
| Diazepam | Diazepam | 28 | suppressed |
| Methotrexate | Methotrexate Sodium | 28 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 27 | 23 |
| Sotalol | Sotalol Hcl | 27 | suppressed |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Valsartan | Valsartan | 26 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 25 | suppressed |
| Levemir Flexpen | Insulin Detemir | 25 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 25 | suppressed |
| Probenecid-Colchicine | Probenecid/Colchicine | 25 | suppressed |
| Cilostazol | Cilostazol | 24 | suppressed |
| Metronidazole | Metronidazole | 24 | 21 |
| Betamethasone Valerate | Betamethasone Valerate | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 20 |
| Solifenacin Succinate | Solifenacin Succinate | 23 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 21 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 21 | suppressed |
| Entresto | Sacubitril/Valsartan | 21 | suppressed |
| Glimepiride | Glimepiride | 21 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 21 | suppressed |
| Ketoconazole | Ketoconazole | 20 | suppressed |
| Methimazole | Methimazole | 20 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Lubiprostone | Lubiprostone | 17 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | 11 |
| Xifaxan | Rifaximin | 16 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Veo Insulin Syringe | Syringe And Needle,insulin,1ml | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Armour Thyroid | Thyroid,pork | 13 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 13 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 12 | suppressed |
| Buprenorphine | Buprenorphine | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 12 | suppressed |
| Hydrocodone-Ibuprofen | Hydrocodone/Ibuprofen | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Nayzilam | Midazolam | 12 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 12 | suppressed |
| Ubrelvy | Ubrogepant | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 11 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 11 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $301.32 · 17 records | AstraZeneca Pharmaceuticals LP | CAPLYTA, FARXIGA, JARDIANCE, QULIPTA, TONMYA, TRELEGY ELLIPTA, UBRELVY, VRAYLAR | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error